Prime Medicine, Inc.
NASDAQ:PRMEBiotechnology
-$0.04 today
- Market cap
- $694.94M
- Beta
- 2.31
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.12
Volume 4.62M
Average 2.47M
PRME Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Prime Medicine, Inc.NASDAQ: PRME
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) growth accelerates
Q1 FY2026 weighted avg shares (diluted) of 177.1M shares rose 35.3% year over year, ahead of the +26.0% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 19.0% from the prior quarter. Over 3 fiscal years it compounded at +15.2% a year.
Context
- Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +35.3% holds above the trailing-twelve-month pace of +26.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 148.76M USD
- Year-over-year change
- +25.4%
- 4-year CAGR
- +11.6%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 148.76M | +25.4% |
| FY2024 | 2024-12-31 | 118.6M | +30.4% |
| FY2023 | 2023-12-31 | 90.97M | -6.4% |
| FY2022 | 2022-12-31 | 97.21M | +1.5% |
| FY2021 | 2021-12-31 | 95.73M | — |
Weighted Avg Shares (Diluted) vs competitors
How PRME compares with its peers on the latest reported figures
- PRME's LTM Mar 2026 weighted avg shares (diluted) of 153.89M shares is the highest of the 7 companies compared; the peer median is 94.49M shares.
- Its year-over-year change of +26.0% is the highest of 7, against a peer median of +8.8%.
- Over three fiscal years its annual growth of +15.2% compares with a peer median of +10.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 153.89M | +26.0% | +15.2% | |
| LTM Mar 2026 | 110.2M | +9.3% | +12.1% | |
| LTM Jun 2026 | 103.77M | +17.0% | +12.2% | |
| LTM Sep 2026 | 94.81M | +8.4% | +5.0% | |
| LTM Mar 2026 | 94.18M | +3.6% | +15.4% | |
| LTM Mar 2026 | 90.28M | +9.3% | +8.9% | |
| LTM Mar 2026 | 58.14M | +2.6% | +1.0% | |
SCTXScribe Therapeutics Inc. | — | — | — | — |
| Peer median (excluding PRME) | 94.49M | +8.8% | +10.5% | |
Competitors are the stored peer set for PRME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 2.98M | 4.63M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 7.32M |
| Gross Profit | 0 | 0 | 0 | 2.98M | (2.69M) |
| Gross Margin | — | — | — | 100.0% | -58.1% |
| Research & Development | 70.55M | 86.73M | 147.91M | 155.29M | 160.64M |
| Selling, General & Admin | 13.92M | 29.82M | 43.39M | 50.16M | 52.35M |
| Operating Expenses | 84.47M | 116.54M | 204.79M | 205.45M | 205.66M |
| Depreciation & Amortization | 568K | 2.22M | 4.65M | 6.13M | 5.38M |
| EBITDA | (165.29M) | (120.55M) | (186.64M) | (189.75M) | (195.76M) |
| EBITDA Margin | — | — | — | -6361.2% | -4226.2% |
| Operating Income | (84.47M) | (116.54M) | (204.79M) | (202.47M) | (208.35M) |
| Operating Margin | — | — | — | -6787.4% | -4498.1% |
| Interest Income | 0 | 0 | 0 | 3.52M | 4.15M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (81.38M) | (6.23M) | 6.38M | 6.59M | 7.21M |
| Income Before Tax | (165.85M) | (122.77M) | (198.41M) | (195.88M) | (201.14M) |
| Pre-Tax Margin | — | — | — | -6566.6% | -4342.4% |
| Income Tax Expense | (486K) | (948K) | (279K) | 0 | 0 |
| Net Income | (165.37M) | (121.82M) | (198.13M) | (195.88M) | (201.14M) |
| Net Margin | — | — | — | -6566.6% | -4342.4% |
| EPS (Basic) | (1.92) | (1.46) | (2.18) | (1.65) | (1.35) |
| EPS (Diluted) | (1.92) | (1.46) | (2.18) | (1.65) | (1.35) |
| Weighted Avg Shares | 95.73M | 97.21M | 90.97M | 118.6M | 148.76M |
| Weighted Avg Shares (Diluted) | 95.73M | 97.21M | 90.97M | 118.6M | 148.76M |
Prime Medicine, Inc.
NASDAQ:PRME
Intrinsic Alpha fair value
Locked
Current Price
$3.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.